 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Aprea Therapeutics
APRE
conference date: November 7, 2024 press release only
Aprea Therapeutics Cancer Therapy Platform Is Promising [July 21, 2020 at Seeking Alpha]
| 2024 | |||
| Aprea Therapeutics Q1 2024 |
Aprea Therapeutics Q1 2024 |
Aprea Therapeutics Q1 2024 |
|
| May 14, 2024 | Aug. 12, 2024 | Nov. 7. 2024 | |
| 2023 | |||
| Aprea Therapeutics Q1 2023 |
Aprea Therapeutics Q2 2023 |
Aprea Therapeutics Q3 2023 |
Aprea Therapeutics Q4 2023 |
| May 15, 2023 | Aug. 10, 2023 | Nov. 9, 2023 | Mar. 26, 2024 |
| 2022 | |||
| Aprea Therapeutics Q1 2022 |
Aprea Therapeutics Q2 2022 Press Release |
Aprea Therapeutics Q3 2022 Press Release |
Aprea Therapeutics Q4 2022 Press Release |
| May 16, 2022 | August 11, 2022 | Nov. 9, 2022 | March 30, 2023 |
| 2021 | |||
| Aprea Therapeutics Q1 2021 release |
Aprea Therapeutics Q2 2021 release |
Aprea Therapeutics Q3 2021 summary |
Aprea Therapeutics Q4 2021 summary |
| May 6, 2021 | Aug. 12, 2021 | Nov. 8, 2021 | March 15, 2022 |
| 2020 | |||
| Aprea Therapeutics Q1 2020 release |
Aprea Therapeutics Q2 2020 release |
Aprea Therapeutics Q3 2020 release |
Aprea Therapeutics Q4 2020 release |
| May 15, 2020 | Aug. 11, 2020 | Nov. 5, 2020 | March 16, 2021 |
Aprea Therapeutics (APRE) is a clinical-stage biotechnology company specializing in therapies for cancers with TP53 mutations.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALLO |
| ALNY |
| AMAT |
| AMGN |
| BIIB |
| BMY |
| CDTX |
| CLDX |
| FATE |
| GILD |
| GLYC |
| ILMN |
| INO |
| MCHP |
| MRNA |
| PLX |
| REGN |
| RNA |
| SAGE |
| SYRS |
| TSVT |
| VRTX |
| VSTM |
| WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2023 William P. Meyers